John McCamant, editor of Medical Technology Stock Letter, Berkeley, California. Its model portfolio returned an annualized 39% over five years, compared with 14% for the S&P 500 stock index. BioInvest.com
As the bull market ages some investors are stretching their comfort zones to boost returns. Here are some great investments options to do that.
Pharmaceutical giants are rushing to partner with or acquire small biotechs, providing a big opportunity for investors.
Many investors stop looking for opportunities in tumultuous markets. They become paralyzed and make no changes at all in their…
The odds are stacked against biotech investors. It typically takes at least 10 years and $500 million in funding to…
Four stocks with great promise Hundreds of US companies are trying to develop compounds to attack cancer in innovative ways…